Introduction {#S1}
============

In addition to its role in maintaining calcium--phosphorus homeostasis, vitamin D is a potent modulator of both innate and adaptive immunity, is involved in the regulation of cell growth and differentiation, detoxification of xenobiotics, and activation of monocytes/macrophages ([@B1], [@B2]). These actions of vitamin D are almost entirely dependent on the interaction between the most biologically active form of vitamin D, 1,25-dihydroxyvitamin D~3~ \[1,25(OH)~2~D~3~\], and the vitamin D receptor (VDR) transcription factor. Bound to 1,25(OH)~2~D~3~, the VDR regulates the expression of a myriad of genes ([@B3], [@B4]). Cathelicidin antimicrobial peptide (*CAMP*) and 25-hydroxyvitamin D~3~-24-hydroxylase (*CYP24A1*) are examples of two well-characterized vitamin D target genes, respectively, encoding the cathelicidin antimicrobial peptide (hCAP-18) and multifunctional vitamin D catabolizing enzyme.

Toll-like receptor 2/1 (TLR2/1) triggering activates a signaling cascade inducing both *VDR* ([@B5]) and *CYP27B1* in monocytes/macrophages. CYP27B1 catalyzes *de novo* production of 1,25(OH)~2~D~3~ from accumulated 25(OH)D~3~; delivered to the cells *via* the vitamin D binding protein (DBP), encoded by *GC*. The liganded VDR--transcription factor complex binds to vitamin D response elements (VDREs) in *CAMP*, activating *CAMP* expression and the production of hCAP-18. hCAP-18 is synthesized as a proprotein consisting of an N-terminal cathelin domain and a C-terminal LL-37 domain ([@B6]). While the cathelin domain is a cysteine protease inhibitor with broad spectrum antibacterial activity ([@B7]), LL-37 directly inhibits mycobacterial replication ([@B5], [@B8]), has antifungal activity against *Candida albicans* ([@B9]), and antiviral activity against HIV ([@B10]).

Since *CAMP* expression is dependent on vitamin D, and vitamin D deficiency has been linked to several infectious diseases including tuberculosis ([@B11]), sepsis ([@B12]), bacterial infections after kidney transplants ([@B13]), and HIV ([@B14]), it is not surprising that more than 100 clinical trials have assessed the efficacy of vitamin D supplementation as adjunct therapy in the treatment of various infectious diseases. However, the outcome of clinical trials has been conflicting and this is often attributed to differences in study design, baseline vitamin D status of participants, and outcome measurements. In fact, it appears that individuals can be classified into three groups: (i) those with a low response, (ii) those with a medium response, and (iii) those with a high response to vitamin D supplementation ([@B15]). These interindividual differences may result from variation in the regulation of *VDR* expression at both a genetic and epigenetic level ([@B16]). For example, VDR function to transactivate *CAMP* is influenced by the VDR single nucleotide polymorphism (SNP) *Fok*I (rs2228570) and ethnicity ([@B17]), while vitamin D insensitivity in breast cancer cells has been attributed to CpG methylation of the *VDR* primary promoter ([@B18]). Thus, both genetics and epigenetics have the potential to influence the response to vitamin D. Indeed, a double-blind randomized controlled trial assessing the impact of high-dose vitamin D~3~ during intensive-phase antimicrobial treatment of pulmonary tuberculosis showed that vitamin D only increased the time for sputum culture conversion in participants carrying the CC genotype of the *VDR* SNP *Taq*I (rs731236) ([@B19]). Additionally, *VDR* expression is influenced by the environment. For example, narrow-band UVB induces miRNA-125b ([@B20]), which directly regulates *VDR* mRNA translation, decreasing VDR protein level ([@B21], [@B22]). Seasonal variation in ultraviolet index (UVI) further correlates with circulating vitamin D ([@B23]). Thus, seasonal variation in UVI directly influences VDR function by altering the availability of the free 1,25(OH)~2~D~3~. Indirectly, changes in 1,25(OH)~2~D~3~ concentration may itself regulate *VDR* expression through multifunctional, 1,25(OH)~2~D~3~-responsive, enhancers located within the *VDR* itself ([@B24]). The complex regulation of the *VDR* through genetics, epigenetics, and environment ([@B16]) may therefore provide insight into inter-individual variation in response to vitamin D and the efficacy of vitamin D to enhance immune function.

Here, we evaluate (1) the effect of *VDR* methylation on the TLR2/1-VDR signaling pathway and (2) the impact of genetic and environmental factors on differential immune signaling. It was hypothesized that VDR-mediated TLR2/1 signaling is influenced by a combination of environment, epigenetics and genetics, collectively influencing differential innate immunity in healthy South Africans. Using an *in vitro* model, stimulating monocytes from healthy individuals with a TLR2/1 elicitor, we avoided pathogen-mediated changes in DNA methylation ([@B25], [@B26]).

Results presented here provide support for multifactorial regulation of VDR-mediated, TLR2/1 signaling, involving interaction between environment, epigenetics, and genetics. UVI influences 25(OH)D~3~ status, which regulates VDR expression through *VDR* methylation, while enhancing the extent and rate of VDR transactivation of *CAMP* encoding the antimicrobial peptide hCAP-18.

Materials and Methods {#S2}
=====================

Sample Collection and Environment {#S2-1}
---------------------------------

In accordance with the Declaration of Helsinki, the Human Research Ethics Committee of the South African National Blood Service (SANBS HREC clearance certificate number 2010/01) and the Ethics Committee, Faculty of Science, University of Johannesburg (2010/06/03) approved the study. After written informed consent, the SANBS collected blood from randomly selected healthy Black (*n* = 50; age 17--62 years; 25 males and 25 females) and White (*n* = 50; age 17--69 years; 25 males and 25 females) South Africans living in Gauteng, SA. Samples were collected across all seasons, though no White individuals were collected in winter for functional analysis. UVI was obtained from the South African Weather Service weather station in Irene, Pretoria, Gauteng. As 25(OH)D~3~ has a half-life of 2--4 weeks in circulation ([@B27]), the approximate UVI that each individual could have been exposed to was calculated as the 4-week average before blood collection, using the average hourly UVI between 11.00 a.m. and 14.00 p.m. across the years of sample collection (2011--2014).

Quantification of Circulating 25(OH)D~3~ {#S2-2}
----------------------------------------

Liquid chromatography tandem mass spectrometry (LC-MS/MS) facilitated quantification of 25(OH)D~3~ concentration in the Department of Clinical Biochemistry, University Hospital of South Manchester (UK), including four human serum pools from the Vitamin D External Quality Assessment Scheme (DEQAS, UK). A concentration of ≥50 nmol/L was considered normal/sufficient ([@B28]). 25(OH)D~3~ concentration was below the detection limit (3 nmol/L) in four Black samples, while sample was insufficient for six Blacks and eight Whites.

Bioinformatics {#S2-3}
--------------

To identify putative functional loci that could influence *VDR* expression and function through genetic and/or epigenetic mechanisms, a bioinformatics workflow was developed (Methods S1.1, Figures S1 and S2, and Table S1 in Supplementary Material).

DNA Methylation Analysis {#S2-4}
------------------------

Monocytes were isolated and gDNA extracted, at time zero, as previously described ([@B17]). *VDR* methylation analysis by bisulfite pyrosequencing was outsourced to EpigenDx, Inc. (MA, USA). Selected sites typed included 10 CpGs in CpG island (CGI) 1066 spanning enhancer U3 (chr12:48340628-48340806, hg19), 56 CpGs in CGI 1062 spanning the primary promoter (chr12:48299359-48298799), 12 CpGs in CGI 1061 spanning exon 3 (chr12:48258845-48259024), and 18 CpGs in CGI 1060 spanning exon 9 (chr12:48238512-48238799). CpGs were numbered in the 5′--3′ direction.

Genotyping {#S2-5}
----------

Genotyping by pyrosequencing was outsourced to EpigenDx, Inc. (MA, USA). Typed SNPs included *GC* rs7041, rs4588, and rs146681395; *TLR1* rs5743551 (A7202G), rs146940675, rs4833095 (N248S), rs111807776, rs143576765, rs5743618 (I602S), rs151036585, rs5743613 (P315L), rs185747096, rs146782074, and rs200631178; *TLR2* rs3804099 (T597C); *TiRAP* rs8177374 (S180L) and rs141792148; *VDR* rs11168312, rs11568820 (Cdx-2), rs182743714, rs184448883, rs4516035 (GATA), rs2228570 (*Fok*I), rs187018098, rs71951818, rs1544410 (*Bsm*I), rs7975232 (*Apa*I), rs731236 (*Taq*I), and rs4987032; *CYP24A1* rs6068812; and *DMNT3A* rs1550117 and rs112621472.

Monocyte/Macrophage Culture and Treatment {#S2-6}
-----------------------------------------

To estimate TLR2/1 pathway efficacy, *VDR* mRNA, VDR protein, *CAMP* mRNA, hCAP-18 peptide, and *CYP24A1* mRNA, hereafter referred to as functional variables, were quantified following different treatments of monocyte/macrophage cultures that were established as previously described ([@B17]). Some monocytes were retained for functional analysis at time zero (baseline). The rest were settled in culture for 16 h prior to 24 h treatment with the vehicle control, 1,25(OH)~2~D~3~ (10 nM, Sigma Aldrich, St Louis, MO, USA), the TLR2/1 elicitor Pam~3~CSK~4~, (6.5 µg/ml culture media, EMC microcollections, Tuebingen, Germany), or both the elicitor and 1,25(OH)~2~D~3~.

mRNA and Protein Quantification {#S2-7}
-------------------------------

The relative level of *VDR, CAMP*, and *CYP24A1* mRNA was quantified by RT-qPCR and VDR protein and intracellular hCAP-18 peptide by flow cytometry as previously described ([@B17]). Gene normalization was performed against two stably expressed reference genes: ubiquitin C (*UBC*) and tyrosine-3-monooxygenase/tryptophan-5-monooxygenase activation protein, zeta polypeptide (*YWHAZ*). Gene expression was quantified using the comparative CT method according to the MIQE guidelines, using inter-run calibrators and qBASE^PLUS^ software. To compensate for variability in fluorescence readings between experiments on the flow cytometer, the median fluorescence intensity (MFI) of broad-spectrum calibration beads was used to normalize data and thereby provide a calibrator for instrument-related variation in the flow cytometry readings over time. For hCAP-18, mouse IgG~1~ anti-human hCAP-18 primary antibodies (10 µg/ml, Abcam, Cambridge, UK) and APC-conjugated goat anti-mouse IgG1 secondary antibodies (2 µg/mL, Abcam, Cambridge, UK) were used. Western blotting facilitated tracing of hCAP-18 processing and secretion (Methods S1.2 in Supplementary Material).

Statistical Analysis {#S2-8}
--------------------

IBM^®^ SPSS^®^ Statistics (v 23; SPSS Inc., Chicago, IL, USA) and SIMCA (v 14; Umetrics, Umea, Sweden) facilitated statistical analysis. Normal distributions were obtained by natural logarithm (ln) transformation of all functional data, except VDR protein. Correlation coefficients were computed using Pearson or Spearman's rho. A general linear model was used for multivariate analysis of variance to assess main effects and factor interaction. Mann--Whitney *U* tested methylation differences. Pearson's Chi-square test for independence assessed SNP distribution. Orthogonal projections to latent structures discriminant analysis (OPLS-DA, Methods S1.3 and Figures S3 and S4 in Supplementary Material) facilitated the study of the multivariate effect of *VDR* methylation, SNPs, and environment on TLR2/1-VDR signaling.

Results {#S3}
=======

Differences in Plasma 25(OH)D~3~ Concentration Are Influenced by Race and Season {#S3-1}
--------------------------------------------------------------------------------

Plasma 25(OH)D~3~ concentration was quantified by LC-MS/MS (Figure [1](#F1){ref-type="fig"}). Race had a significant main effect on 25(OH)D~3~ concentration (*P* \< 0.001). Overall, Blacks were deficient (\<50 nmol/L) with a significantly lower 25(OH)D~3~ concentration (*P* \< 0.010) than Whites, who had normal levels (≥50 nmol/L). Race interacted significantly with season (*P* \< 0.010), showing a lower 25(OH)D~3~ concentration in Blacks in winter (*P* \< 0.050) and spring (*P* \< 0.001), but not in summer and autumn.

![Race and season influenced plasma 25(OH)D~3~ concentration. The error bar plot shows the mean plasma 25(OH)D~3~ concentration, quantified by liquid chromatography tandem mass spectrometry, for healthy Black (filled markers, *n* = 50) and White (open markers, *n* = 53) South Africans, collected in winter (Black *n* = 17, White *n* = 10), spring (Black *n* = 10, White *n* = 16), summer (Black *n* = 10, White *n* = 11), and autumn (Black *n* = 13, White *n* = 16). Blacks were deficient (\<50 nmol/L), having a significantly lower plasma 25(OH)D~3~ concentration than Whites in winter (\**P* \< 0.050), spring (\*\*\**P* \< 0.001), and overall (\*\**P* \< 0.010). Overall, whites had normal 25(OH)D~3~ levels (≥50 nmol/L, ≤125 nmol/L), with a significantly higher plasma 25(OH)D~3~ concentration in spring compared to autumn (+*P* \< 0.050). *P*-Values were adjusted using Bonferroni correction. Error bars show the unadjusted least significant difference at *P* \< 0.050. The dotted line indicates the border between normal and deficient.](fimmu-08-01048-g001){#F1}

*VDR* Methylation Differs between Races {#S3-2}
---------------------------------------

To assess the impact of *VDR* methylation on TLR2/1-VDR signaling, *VDR* methylation was quantified by bisulfite pyrosequencing. Regional methylation (Figure [2](#F2){ref-type="fig"}A) was compared between Blacks and Whites across the *VDR* in key CGIs identified through a bioinformatics workflow (Methods S1.1, Figures S1 and S2, and Table S1 in Supplementary Material). Comparing regional methylation, Whites had significantly lower levels at CGI 1062 (*P* \< 0.001) and CGI 1060a (CpG 1-5, 5′ of *Taq*I, Figure [2](#F2){ref-type="fig"}A, *P* \< 0.010) than Blacks, but higher levels at CGI 1060b (CpG 7-18, 3′ of *Taq*I, Figure [2](#F2){ref-type="fig"}A, *P* \< 0.001). Significant racial differences in site-specific methylation (Results S2.2 and Figure S5 in Supplementary Material) were common in CGI 1062 (27/56) and 1060 (10/18), but less so in CGI 1066 (1/10) and1061 (3/12).

![Race differences in regional vitamin D receptor (*VDR*) methylation. Box-and-whisker plots show the spread of regional methylation, quantified by bisulfite pyrosequencing, at the selected CpG islands (CGIs) **(A)** in context of *VDR* non-coding (unfilled) and coding exons (filled) and key single-nucleotide polymorphisms **(B)**; CGI 1066 spanning an enhancer, 1062 the primary promoter, 1061 exon 3 and 1060 exon 9, and the promoter of a non-coding transcript. Compared to Black South Africans (filled boxes, *n* = 50), methylation in Whites (open boxes, *n* = 50) was significantly lower in CGI 1062 (\*\*\**P* \< 0.001) and 1060a (\*\**P* \< 0.010), but higher in CGI 1060b (\*\*\**P* \< 0.001). Box-and-whisker plots show the median (line in box), interquartile range (IQR, height of box), 95% CI (whiskers, extending to 1.5 IQRs or minimum and maximum values if no case has a value in that range), outliers (○, between 1.5 IQRs and 3 IQRs from the end of a box), and extreme outliers (◻, more than 3 IQRs from the end of a box). Site-specific methylation is shown in Figures S5A--D in Supplementary Material.](fimmu-08-01048-g002){#F2}

TLR-VDR Pathway Genetics Differs between Races {#S3-3}
----------------------------------------------

To assess genetic variation between individuals in the TLR2/1-VDR signaling pathway, SNPs in several genes of the pathway and in the *de novo* methyltransferase enzyme, *DNMT3A*, were genotyped by pyrosequencing. Several SNPs, including *DNMT3A* SNPs, were monomorphic in the study population. Except for *VDR Bsm*I and *Taq*I, the frequency distribution of polymorphic SNPs differed significantly between Blacks and Whites (Table [1](#T1){ref-type="table"}). The 1000 Genomes Deep Catalog of Human Genetic Variation confirmed race-specific genotype frequency distribution, also for *Bsm*I and *Taq*I though not for *Apa*I, comparing Africans (Yoruba) and Caucasians (Table S2 in Supplementary Material).

###### 

Differential genotype distribution for polymorphic single-nucleotide polymorphism (SNPs) in the toll-like receptor (TLR)--vitamin D receptor (VDR) pathway in Black and White South Africans.

  Gene                                                  Genotype[^a^](#tfn1){ref-type="table-fn"}   Black     White     Pearson's chi-square                 
  ----------------------------------------------------- ------------------------------------------- --------- --------- ---------------------- --- --------- -------
  ***GC***                                                                                                                                                   
  rs7041                                                GG                                          1 (2)     10 (22)   60                     2   \<0.001   0.806
                                                        GT                                          2 (4)     30 (65)                                        
                                                        TT                                          43 (93)   6 (13)                                         
  rs4588                                                AA                                          2 (4)     1 (2)     8                      2   \<0.050   0.298
                                                        AC                                          6 (13)    18 (39)                                        
                                                        CC                                          38 (83)   27 (59)                                        
                                                                                                                                                             
  ***TLR1***                                                                                                                                                 
  rs5743551 (A7202G)                                    AA                                          1 (2)     26 (53)   61                     2   \<0.001   0.790
                                                        AG                                          6 (12)    19 (39)                                        
                                                        GG                                          43 (86)   4 (8)                                          
  rs4833095 (N248S)                                     AA                                          2 (4)     24 (52)   43                     2   \<0.001   0.684
                                                        AG                                          9 (20)    19 (37)                                        
                                                        GG                                          34 (76)   5 (11)                                         
  rs5743618 (I602S)                                     CC                                          0 (0)     0 (0)     57                     1   \<0.001   0.796
                                                        CA                                          2 (4)     40 (83)                                        
                                                        AA                                          45 (96)   8 (17)                                         
                                                                                                                                                             
  ***TLR2***                                                                                                                                                 
  rs3804099 (T597C)                                     CC                                          28 (64)   12 (25)   21                     2   \<0.001   0.484
                                                        CT                                          15 (34)   22 (47)                                        
                                                        TT                                          1 (2)     13 (28)                                        
                                                                                                                                                             
  ***TIRAP***                                                                                                                                                
  rs8177374 (S180L)                                     AA                                          0 (0)     1 (2)     16                     2   \<0.001   0.402
                                                        AG                                          1 (2)     15 (31)                                        
                                                        GG                                          47 (98)   33 (67)                                        
                                                                                                                                                             
  ***VDR***                                                                                                                                                  
  rs11568820 (Cdx-2)                                    AA                                          25 (57)   3 (6)     43                     2   \<0.001   0.683
                                                        AG                                          17 (39)   14 (29)                                        
                                                        GG                                          2 (5)     31 (65)                                        
  rs4516035 (GATA)                                      AA                                          44 (90)   16 (33)   34                     2   \<0.001   0.587
                                                        AG                                          4 (8)     28 (57)                                        
                                                        GG                                          1 (2)     5 (10)                                         
  rs2228570 (*Fok*I[^c^](#tfn3){ref-type="table-fn"})   TT/ff                                       2 (4)     12 (24)   17                     2   \<0.001   0.413
                                                        TC/Ff                                       12 (25)   21 (43)                                        
                                                        CC/FF                                       35 (71)   16 (33)                                        
  rs1544410 (*Bsm*I)                                    AA/BB                                       2 (4)     8 (16)    4                      2   ns        0.213
                                                        AG/bB                                       21 (43)   20 (42)                                        
                                                        GG/bb                                       26 (53)   20 (42)                                        
  rs7975232 (*Apa*I)                                    TT/AA                                       27 (55)   13 (27)   12                     2   \<0.010   0.351
                                                        TG/Aa                                       21 (43)   27 (55)                                        
                                                        GG/aa                                       1 (2)     9 (18)                                         
  rs731236 (*Taq*I)                                     TT/TT                                       21 (43)   21 (43)   2                      2   ns        0.152
                                                        TC/Tt                                       23 (47)   18 (37)                                        
                                                        CC/tt                                       5 (10)    10 (20)                                        

*^a^Alleles used in genotypes represent those of the reverse strand on which the gene is located*.

*^b^Cramer's V indicates effect size and varies between 0 and 1: small 0.07--0.20, medium 0.21--0.34, and large 0.35--1.00*.

*^c^*Fok*I, *Bsm*I, *Apa*I, and *Taq*I genotypes show nucleotides/restriction sites presence (lowercase) or absence (capital)*.

Multivariate Effects of Race, Plasma 25(OH)D~3~ Status, Season, and Treatment on Functional Variables upon Elicitation of TLR2/1-VDR Signaling {#S3-4}
----------------------------------------------------------------------------------------------------------------------------------------------

To assess the efficacy of the TLR2/1-VDR signaling regarding functional variables in the pathway (*VDR* mRNA, VDR protein, *CAMP* mRNA, hCAP-18, and *CYP24A1* mRNA), multivariate analysis of the effect of race, 25(OH)D~3~ status, season, and treatment (with/without *in vitro* 1,25(OH)~2~D~3~ supplementation and/or TLR2/1 elicitation) was performed (Table [2](#T2){ref-type="table"}). Treatment had a significant main effect on functional variables (Figure [3](#F3){ref-type="fig"}), while season, race, and 25(OH)D~3~ status showed several complex interactions regarding *VDR* mRNA and VDR protein (Figure [4](#F4){ref-type="fig"}), *CAMP* mRNA and *CYP24A1* mRNA (Figure [5](#F5){ref-type="fig"}) and hCAP-18 (Figure [6](#F6){ref-type="fig"}). TLR2/1 elicitation induced VDR protein (Figure [3](#F3){ref-type="fig"}B, *P* \< 0.001), while 1,25(OH)~2~D~3~ induced *CAMP* mRNA and *CYP24A1* mRNA (Figures [3](#F3){ref-type="fig"}C,E, *P* \< 0.001). Considering interactions, 25(OH)D~3~-deficient Blacks had significantly lower *VDR* mRNA in summer than deficient Whites or Whites and Blacks with a normal 25(OH)D~3~ status (*P* \< 0.050, Figure [4](#F4){ref-type="fig"}A). In contrast, 25(OH)D~3~-deficient Whites had significantly lower *VDR* mRNA in autumn than deficient Blacks or Whites and Blacks with a normal 25(OH)D~3~ status (*P* \< 0.050). VDR protein dropped significantly in summer and autumn for Whites and Blacks, respectively, showing a significant race difference in summer (*P* \< 0.050, Figure [4](#F4){ref-type="fig"}B). *CAMP* mRNA increased significantly from summer to autumn in Whites, being significantly higher than Blacks (*P* \< 0.050, Figure [5](#F5){ref-type="fig"}A). Whites with a normal 25(OH)D~3~ status had significantly higher *CYP24A1* mRNA than 25(OH)D~3~-deficient Whites or Blacks and Blacks with a normal 25(OH)D~3~ status (*P* \< 0.050, Figure [5](#F5){ref-type="fig"}B). A notable decrease in hCAP-18 was observed in Whites from spring through summer to autumn being significantly higher in spring and significantly lower in autumn, compared to Blacks (*P* \< 0.050, Figure [6](#F6){ref-type="fig"}A). All individuals with a normal 25(OH)D~3~ status showed a similar, significant decrease in hCAP-18 from spring to autumn (*P* \< 0.050, Figure [6](#F6){ref-type="fig"}B). Blacks with a normal 25(OH)D~3~ status had significantly more hCAP-18, than normal Whites and deficient Blacks or Whites (*P* \< 0.050, Figure [6](#F6){ref-type="fig"}C). To confirm that the intracellular decrease in hCAP-18 in response to seasons with higher 1,25(OH)~2~D~3~ reflects hCAP-18 processing and LL-37 secretion, we performed Western blotting on 20 additional randomly selected healthy Black (*n* = 10) and White (*n* = 10) South Africans. These individuals, collected in winter and for whom no other variables were quantified, were also included in 25(OH)D~3~ quantification (shown in Figure [1](#F1){ref-type="fig"}). Western blotting showed individual-specific hCAP-18 processing and LL-37 secretion, which depended on 25(OH)D~3~ status, extent of 1,25(OH)~2~D~3~ supplementation, and incubation time (Figure [7](#F7){ref-type="fig"}). For example, an individual with a sufficient 25(OH)D~3~ status (\>50 nmol/L, Figure [7](#F7){ref-type="fig"}A) had the highest level of intracellular LL-37 under control condition and already secreted LL-37 upon TLR2/1 elicitation at 16 h, and secreted even more with moderate 1,25(OH)~2~D~3~ supplementation (10 nM) or at 24 h. However, with excessive (50 nM) supplementation, the individual secreted less (16 h) or none (24 h). In contrast, 25(OH)D~3~-deficient individuals secreted LL-37 slower and required at least 50 nM of 1,25(OH)~2~D~3~ to secrete at 16 h (Figure [7](#F7){ref-type="fig"}C). An individual with severe 25(OH)D~3~ deficiency (23.2 nmol/L) secreted LL-37 only after 24 h in the presence of 50 nM 1,25(OH)~2~D~3~ (Figure [7](#F7){ref-type="fig"}D). It should be noted that secreted LL-37 was undetectably low in 13 of the 20 randomly selected individuals subjected to Western blotting.

###### 

Multivariate main and interaction effects of season, race, 25(OH)D~3~ status, and treatment on the functional variables marking TLR2/1 vitamin D receptor (VDR)-mediated signaling.

                                                  Multivariate *P*-value[^a^](#tfn4){ref-type="table-fn"}   Tests of between-subjects                                                        
  ----------------------------------------------- --------------------------------------------------------- -------------------------------------- ------------- ------------- ------------- -------------
  Season                                          0.000\*\*\*                                               0.089                                  0.003\*\*     0.000\*\*\*   0.000\*\*\*   0.000\*\*\*
  Race                                            0.000\*\*\*                                               0.146                                  0.617         0.000\*\*\*   0.000\*\*\*   0.000\*\*\*
  25(OH)D~3~ status                               0.135                                                     na.[^b^](#tfn5){ref-type="table-fn"}   na.           na.           na.           na.
  Treatment                                       0.000\*\*\*                                               0.999                                  0.000\*\*\*   0.000\*\*\*   0.385         0.000\*\*\*
  Season × race                                   0.000\*\*\*                                               0.000\*\*\*                            0.000\*\*\*   0.010\*       0.000\*\*\*   0.543
  Season × 25(OH)D~3~ status                      0.000\*\*\*                                               0.024\*                                0.055         0.259         0.001\*\*     0.000\*\*\*
  Season × treatment                              1.000                                                     na.                                    na.           na.           na.           na.
  Race × 25(OH)D~3~ status                        0.000\*\*\*                                               0.866                                  0.346         0.092         0.000\*\*\*   0.001\*\*
  Race × treatment                                0.957                                                     na.                                    na.           na.           na.           na.
  25(OH)D~3~ status × treatment                   0.999                                                     na.                                    na.           na.           na.           na.
  Season × race × 25(OH)D~3~ status               0.002\*\*                                                 0.001\*\*                              0.848         0.530         0.069         0.012\*
  Season × race × treatment                       1.000                                                     na.                                    na.           na.           na.           na.
  Season × 25(OH)D~3~ status × treatment          1.000                                                     na.                                    na.           na.           na.           na.
  Race × 25(OH)D~3~ status × treatment            0.919                                                     na.                                    na.           na.           na.           na.
  Season × race × 25(OH)D~3~ status × treatment   0.998                                                     na.                                    na.           na.           na.           na.
  Levene's[^c^](#tfn6){ref-type="table-fn"}                                                                 0.093                                  0.121         0.080         0.598         0.004\*\*

*^a^Multivariate Pillai's trace statistic is significant at \*P \< 0.050, \*\*P \< 0.010, and \*\*\*P \< 0.001*.

*^b^na. Not applicable for testing due to multivariate P \> 0.050*.

*^c^Levene's Test of Equality of Error Variances is significant at \*\*P \< 0.010*.

![Differential vitamin D receptor (VDR)-mediated innate immune response to toll-like receptor (TLR) 2/1 elicitation, with or without *in vitro* 1,25(OH)~2~D~3~ supplementation. The error bar plots show mean levels for *VDR* mRNA **(A)**, VDR protein **(B)**, *CAMP* mRNA **(C)**, hCAP-18 peptide **(D)**, and *CYP24A1* mRNA **(E)**, for healthy South Africans (*n* = 100). Gene expression (mRNA) was quantified by RT-qPCR and protein or peptide level by flow cytometry. Significant treatment effects are shown (\*\*\**P* \< 0.001). All significant differences were maintained after Bonferroni correction. Error bars show the least significant difference at *P* \< 0.050.](fimmu-08-01048-g003){#F3}

![Interaction between season, race, and 25(OH)D~3~ status influence vitamin D receptor (*VDR*) mRNA and protein level. The line graphs show the interaction effects for *VDR* mRNA **(A)** and protein **(B)** level, quantified by RT-qPCR and flow cytometry, in monocytes/macrophages from healthy Black (*n* = 34) and White (*n* = 41) South Africans. Season, race, and 25(OH)D~3~ status interacted significantly to influence *VDR* mRNA (*P* \< 0.001), while season and race showed interaction effects on VDR protein (*P* \< 0.001). Error bars show the least significant difference at *P* \< 0.050. nc. = not collected.](fimmu-08-01048-g004){#F4}

![Interaction between season, race, and 25(OH)D~3~ status influence vitamin D receptor (VDR) transactivation of cathelicidin antimicrobial peptide (*CAMP*) and 25-hydroxyvitamin D~3~-24-hydroxylase (*CYP24A1*). The line graphs show the interaction effects for *CAMP* mRNA **(A)** and *CYP24A1* mRNA **(B)** level, quantified by RT-qPCR, in monocytes/macrophages from healthy Black (*n* = 34) and White (*n* = 41) South Africans. Season and race interacted significantly to influence *CAMP* mRNA (*P* \< 0.050), while season, race, and 25(OH)D~3~ status showed interaction effects on *CYP24A1* mRNA levels (*P* \< 0.050). Error bars show the least significant difference at *P* \< 0.050. nc. = not collected.](fimmu-08-01048-g005){#F5}

![Interaction between season, race, and 25(OH)D~3~ status influence intracellular hCAP-18 peptide level. The line graphs show the interaction effects for hCAP-18 peptide level, quantified by flow cytometry, in monocytes/macrophages from healthy Black (*n* = 34) and White (*n* = 41) South Africans. Season and race \[**(A)**, *P* \< 0.001\], season, and 25(OH)D~3~ status \[**(B)**, *P* \< 0.010\], and race and 25(OH)D~3~ status \[**(C)**, *P* \< 0.001\] interacted significantly to influence hCAP-18 levels. Error bars show the least significant difference at *P* \< 0.050. nc. = not collected.](fimmu-08-01048-g006){#F6}

![The rate of hCAP-18 processing and secretion is individual-specific and 1,25(OH)~2~D~3~-dependent. The Western blots and accompanying line graphs (densitometry results) show the relative levels of hCAP-18 (15 kDa) and LL-37 (4 kDa) in monocytes/macrophages \[intracellular, **(A--D)**\] and LL-37 secreted into culture media \[extracellular, **(E--H)**\] in response to toll-like receptor (TLR) 2/1 elicitation in the absence or presence 10 or 50 nM 1,25(OH)~2~D~3~ at 16 h and 24 h. Four individuals from a study of healthy South Africans (*n* = 20) are shown, representing Blacks and Whites of different 25(OH)D~3~ status \[**(A,E)**: 25(OH)D~3~ sufficient White; **(B,F)**: 25(OH)D~3~-deficient White; **(C,G)**: 25(OH)D~3~-deficient Black; and **(D,H)**: 25(OH)D~3~-deficient Black\]. Relative protein or peptide level in monocytes/macrophages or culture media (enriched for proteins \< 50 kDa through ultrafiltration) was quantified and normalized to total protein loaded (dotted line, cathelin; solid line, LL-37). Single dashes on blots, between lanes for LL-37 standard and control sample, indicate the position of hCAP-18 (15 kDa), without signaling peptide (3 kDa, not detected), and LL-37 (4 kDa) cleaved from cathelin (11 kDa, not detected).](fimmu-08-01048-g007){#F7}

Correlation Analysis {#S3-5}
--------------------

To further explore the relation between independent variables (UVI, 25(OH)D~3~ concentration, age and regional methylation) and dependent functional variables, following different treatments, correlation analysis was performed (Table [3](#T3){ref-type="table"}). UVI correlated moderately with circulating 25(OH)D~3~, which in turn showed a moderate, negative correlation with regional methylation of the *VDR* promoter CGI 1062. Regarding inter-CGI correlations, CGI 1066 and 1060b correlated negatively with CGI 1062, 1061, and 1060a. The significant correlation between 25(OH)D~3~ and methylation was maintained irrespective of season, with partial correlations controlling for seasonal changes in UVI yielding similar correlation coefficients (data not shown). Considering functional variables, regional methylation showed moderate correlation with VDR protein under certain treatments: CGI 1066 and 1060b (positive for all treatments but baseline); 1060a (negative for all treatments but baseline); 1062 and 1061 (negative for 1,25(OH)~2~D~3~ and/or TLR2/1 elicitor). As expected, each functional variable showed correlation between all treatments (not shown). In addition, *VDR* mRNA showed a number of moderate positive correlations with *CAMP* mRNA, across a number of treatments, similarly so, *CAMP* with *CYP24A1* mRNA. Age showed a moderate negative correlation with hCAP-18 peptide with TLR2/1 elicitor + 1,25(OH)~2~D~3~ (*r* = −0.330, *P* \< 0.01, *n* = 99).

###### 

Significant correlations between independent environmental variables \[season (UVI), plasma 25(OH)D~3~ concentration\] and dependent TLR2/1-VDR signaling variables, marking *VDR* expression (*VDR* mRNA, VDR protein) and function (*CAMP* mRNA, *CYP24A1* mRNA, hCAP-18 protein)[^a^](#tfn7){ref-type="table-fn"}.

                                                        UVI               Circulating 25(OH)D~3~   All GCIs            CGI 1066           CGI 1062            CGI 1061           CGI 1060            CGI 1060a          CGI 1060b
  ----------------------------------- ----------------- ----------------- ------------------------ ------------------- ------------------ ------------------- ------------------ ------------------- ------------------ ---------------
  Circulating 25(OH)D~3~                                0.396\*\* (71)                                                                                                                                                  
                                                                                                                                                                                                                        
  Regional methylation                All GCIs          ns.               ns.                                                                                                                                           
  CGI 1066                            ns.               ns.               0.478\*\*\* (96)                                                                                                                              
  CGI 1062                            −0.228\* (88)     −0.368\*\* (83)   0.552\*\*\* (96)         ns.                                                                                                                  
  CGI 1061                            ns.               −0.287\*\* (80)   0.262\*\* (96)           −0.399\*\*\* (96)   0.341\*\* (97)                                                                                   
  CGI 1060                            ns.               ns.               0.657\*\*\* (96)         ns.                 0.229\* (99)       0.327\*\* (97)                                                                
  CGI 1060a                           ns.               −0.255\* (82)     0.338\*\* (96)           −0.329\*\* (96)     0.497\*\*\* (99)   0.648\*\*\* (97)    0.435\*\*\* (99)                                          
  CGI 1060b                           ns.               0.298\*\* (81)    0.229\* (95)             0.388\*\*\* (95)    −0.285\*\* (98)    −0.458\*\*\* (96)   0.269\*\* (98)     −0.453\*\*\* (98)                      
                                                                                                                                                                                                                        
  ln *VDR* mRNA                       Baseline          0.326\*\* (84)    0.223\* (78)             ns.                 ns.                ns.                 ns.                ns.                 ns.                ns.
  Control                             0.273\* (84)      ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  1,25(OH)~2~D~3~                     0.307\*\* (83)    0.274\* (77)      ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor                     ns.               0.277\* (77)      ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor + 1,25(OH)~2~D~3~   0.246\* (84)      0.233\* (78)      ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
                                                                                                                                                                                                                        
  VDR protein                         Baseline          −0.276\*\* (87)   ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                ns.
  Control                             ns.               ns.               ns.                      0.349\*\* (94)      ns.                ns.                 ns.                −0.200\* (97)       0.206\* (96)       
  1,25(OH)~2~D~3~                     ns.               ns.               ns.                      0.296\*\* (95)      −0.204\* (99)      ns.                 ns.                −0.317\*\* (98)     0.303\*\* (97)     
  TLR2/1 elicitor                     ns.               ns.               ns.                      0.293\*\* (95)      −0.227\* (99)      −0.236\* (96)       −0.245\* (98)      −0.348\*\*\* (98)   0.201\* (97)       
  TLR2/1 elicitor + 1,25(OH)~2~D~3~   ns.               ns.               ns.                      0.336\*\* (95)      −0.267\*\* (99)    −0.246\* (96)       ns.                −0.362\*\*\* (98)   0.364\*\*\* (97)   
                                                                                                                                                                                                                        
  ln *CAMP* mRNA                      Baseline          ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                ns.
  Control                             0.249\* (83)      ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  1,25(OH)~2~D~3~                     0.308\*\* (84)    ns.               ns.                      −0.268\* (91)       ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor                     0.226\* (82)      0.246\* (77)      ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor + 1,25(OH)~2~D~3~   0.249\* (84)      ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
                                                                                                                                                                                                                        
  ln hCAP-18 peptide                  Baseline          −0.216\* (87)     ns.                      ns.                 ns.                ns.                 0.203\* (95)       ns.                 ns.                −0.202\* (96)
  Control                             −0.214\* (88)     ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  1,25(OH)~2~D~3~                     ns.                                 ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor                     −0.264\* (88)     ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor + 1,25(OH)~2~D~3~   −0.278\*\* (88)   ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
                                                                                                                                                                                                                        
  ln *CYP24A1* mRNA                   Baseline          ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                ns.
  Control                             ns.               ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  1,25(OH)~2~D~3~                     ns.               ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor                     ns.               ns.               ns.                      −0.251\* (91)       ns.                ns.                 ns.                ns.                 ns.                
  TLR2/1 elicitor + 1,25(OH)~2~D~3~   ns.               ns.               ns.                      ns.                 ns.                ns.                 ns.                ns.                 ns.                

*^a^The two-tailed Spearman's rho correlation coefficients were significant at \*P \< 0.050, \*\*P \< 0.010, and \*\*\*P \< 0.001. The adjusted significance threshold for multiple comparisons is \*\*P \< 0.010. The number of cases included for each test is shown in brackets next to the correlation coefficient for significant correlations*.

*CAMP, cathelicidin antimicrobial peptide; CGI, CpG island; CpG, cytosine-phosphate-guanine dinucleotide; CYP24A1, 25-hydroxyvitamin D~3~-24-hydroxylase; ns, not significant; TLR, toll-like receptor; UVI, ultraviolet index; VDR, vitamin D receptor*.

The Combined Impact of Genetics, Epigenetics, and Environment on TLR2/1-VDR Signaling {#S3-6}
-------------------------------------------------------------------------------------

To identify the main variables underlying differential levels of *VDR* and downstream targets (*CAMP*, hCAP-18, and *CYP24A1*), the multivariate OPLS-DA statistical method was performed and validated as described (Methods S1.3 in Supplementary Material). Evaluation of the loadings S-plots (Methods S1.3 and Figure S4 in Supplementary Material) and descriptive assessment of the scores space for each model, identified combined effects of genetics, *VDR* methylation, vitamin D status, and UVI on the efficacy of TLR2/1-VDR signaling, as assessed by the level of functional variables produced in response to various treatments. Functional variables were categorized as above/below average and X (independent) variables that significantly (*P* ≤ 0.050) and/or measurably (≥1.5-fold or ≤0.667) discriminate mean values for above/below average response were recorded with their correlation (Table [4](#T4){ref-type="table"}). Methylation at CGI 1062, CpG 3 significantly and most notably discriminate mean values for above and below average VDR protein level, particularly with TLR2/1 elicitation. Other sizeable methylation--function interactions observed that were significant and occurred in at least two treatments of a functional variable included 1060 CpG 6 \[positive impact on *VDR* mRNA with 1,25(OH)~2~D~3~ supplementation or TLR2/1 elicitation\], 1062 CpG 23 (negative impact on hCAP-18 at control and elicitation, with or without supplementation), and CGI 1060a across several neighboring CpGs \[1060 CpG 1-5, negative impact for 1,25(OH)~2~D~3~ supplementation, TLR2/1 elicitation or both, clustering by 25(OH)D~3~ status in the absence of supplement and by the *Taq*I *VDR* SNP with/without supplement\]. Methylation at CGI 1066, CpG 1-6 also influenced VDR protein level positively following 1,25(OH)~2~D~3~ treatment, with or without TLR2/1 elicitor, showing clustering based on race and SNPs in *VDR* (*Bsm*I, *Apa*I, and *Taq*I), *TLR1* (I602S), and *TIRAP* (S180L), particularly in the presence of supplement. Compared to VDR protein, *CAMP* mRNA level was inversely impacted by CGI 1066, CpG 1-6 methylation, following 1,25(OH)~2~D~3~ treatment, while it clustered only based on 25(OH)D~3~ status and *Taq*I. Methylation of the CpG located at *Taq*I was the only methylation site with significant impact on *VDR* mRNA level following 1,25(OH)~2~D~3~ or TLR2/1 elicitor, but not both. Considering environmental factors, UVI and 25(OH)D~3~ significantly influenced *VDR* mRNA level following treatment with 1,25(OH)~2~D~3~, TLR2/1 elicitor, or both. VDR protein level at baseline and *CAMP* and *CYP24A1* mRNA upon elicitation were significantly influenced by 25(OH)D~3~. 25(OH)D~3~ status and *Taq*I most consistently showed clustering during descriptive assessment of the scores space of computed models. Model construction for hCAP-18 was less favorable and we were unable to identify clustering. Clustering by season, although tested, was not observed.

###### 

Fold change (above/below average means) and correlation for functional variables, significantly and/or prominently, impacted by VDR methylation, 25(OH)D~3~, and UVI, together with population clustering, observed through score space assessment.

  ------------------------------
  ![](fimmu-08-01048-t004.jpg)
  ------------------------------

Discussion {#S4}
==========

Using a healthy South African cohort, we studied the combined effect of *VDR* methylation, TLR2/1-VDR pathway SNPs, and environment on TLR2/1 signaling and inter-individual variation in the response to vitamin D supplementation.

Results support race-related seasonal variation in 25(OH)D~3~ status ([@B29]), though, on average, Blacks were 25(OH)D~3~ deficient irrespective of season (Figure [1](#F1){ref-type="fig"}). Since TLR2/1-VDR signaling to induce *CAMP* greatly depends on the availability of 1,25(OH)~2~D~3~, Black South Africans may have an overall weaker immune response to bacterial pathogens and may benefit from vitamin D supplementation all year round. However, 25(OH)D~3~, season, and race showed complex interactions that influence TLR2/1-VDR signaling, rendering blanket supplementation presumptuous. For example, not all Blacks in the current study were 25(OH)D~3~ deficient (14% were sufficient). Western blotting of secreted LL-37 showed a decreased LL-37 secretion upon supplementation of 25(OH)D~3~ sufficient individuals (Figure [7](#F7){ref-type="fig"}), supporting the proposed U-shaped relationship between serum 25(OH)D~3~ and health ([@B30]).

As expected for regional methylation of expressed genes ([@B31]), *VDR* enhancer (1066) and promoter (1062) CGIs were hypomethylated, while the gene-body CGIs (1061 and 1060) were hypermethylated (Figure [2](#F2){ref-type="fig"}). Blacks had significantly higher methylation at CGI 1062 and CGI 1060a, but lower methylation at 1060b than Whites. The race-specific variation in methylation observed here agrees with Heyn et al. ([@B32]) and Adkins et al. ([@B33]) who independently showed genome-wide methylation differences between populations, contributing to natural variation. Similarly, Andraos et al. ([@B34]) showed significantly higher methylation levels in the Nigerian Yoruba population compared to European Caucasians at several CpG sites within *VDR* CGI 1060. CGI 1060 spans key features; the 5′ splice site for exon 9 (partly encoding the ligand binding domain for VDR), TaqI/CpG 6 embedded in a putative VDRE ([@B35]) and the promoter of an untranslated transcript (AK024830) for which the transcription start site is a few bp downstream of a miRNA-125b target site. Thus, differential methylation within this region of the *VDR* may have profound effects on the expression of *VDR* and subsequent efficacy of the TLR2/1-VDR signaling pathway. Indeed, we have previously shown ethnicity-dependent methylation of *VDR* CGI 1060 to distinguish tuberculosis cases from controls ([@B34]).

The significant correlation between *VDR* methylation and plasma 25(OH)D~3~ supports the proposed relationship between vitamin D and the epigenome ([@B36]--[@B39]). The inverse relationship between vitamin D and *VDR* methylation, especially at the primary promoter-spanning CGI 1062, suggests that in addition to the decrease in ligand, increased promoter methylation may be present in vitamin D-deficient individuals, further dampening the TLR2/1-VDR signal. Thus, vitamin D may interact with the epigenome to influence immune function. Indeed, the higher the methylation at CGI 1062 and 1060a, the less VDR protein is present in response to 1,25(OH)~2~D~3~ supplementation and/or TLR2/1 elicitation (Table [3](#T3){ref-type="table"}).

Besides epigenetic differences, SNP frequency distribution for all, except *VDR Bsm*I and *Taq*I, differed significantly between races with large effect sizes observed for *GC* rs7041, *TLR1* A7202G, N248S and I602S, and *VDR* Cdx-2 (Table [1](#T1){ref-type="table"}). Similar results were obtained for the 1000 Genomes Project's YRI and CEU populations, except for *Taq*I and *Bsm*I being significant, but not *Apa*I (Table S2 in Supplementary Material). These striking differences in frequency distribution of disease-associated or functionally relevant SNPs support the likelihood of inter-individual variation in TLR2/1-VDR signaling, response to vitamin D supplementation and immune function. For example, the two *GC* SNPs rs7041 and rs4588 create the three common Gc/DBP isoforms (Gc~1~F, Gc~1~S, and Gc~2~) showing significant geographical- and race-specific distribution patterns. The Gc~1~F alleles (rs7041: T allele, rs4588: C allele) are more common among African-Americans and Africans, while the Gc~1~S alleles (rs7041: G allele, rs4588: C allele) are more common among Europeans ([@B40], [@B41]). Gc~1~F and Gc~1~S have a stronger affinity for 25(OH)D compared to Gc~2~ ([@B42]), proposed to deliver 25(OH)D more efficiently to target tissues ([@B43]). Gc~1~F/Gc~1~F homozygotes have the lowest DBP level and Gc~1~S/Gc~1~S the highest, yet the bioavailable (unbound or free) 25(OH)D is similar between the isoforms ([@B44]). Thus, the efficacy of 25(OH)D~3~ delivery to target cells may be influenced by genetics and may contribute to the differential response to vitamin D supplementation.

The *in vitro* model used confirmed the induction of VDR by TLR2/1 elicitation ([@B5]) and ligand dependance of VDR transactivation of *CAMP* and *CYP24A1* (Figure [3](#F3){ref-type="fig"}). Observed interactions, regarding race, season and 25(OH)D~3~ status (Figures [4](#F4){ref-type="fig"}--[6](#F6){ref-type="fig"}) supported the observed correlation between UVI and 25(OH)D~3~ status ([@B23]), influencing gene expression and hCAP-18 processing; both processes seemingly hampered/delayed in Blacks or 25(OH)D~3~ deficient individuals. This was also observed for LL-37 secretion in Western blot findings (Figure [7](#F7){ref-type="fig"}). Significant down regulation of VDR protein in Whites in summer likely reflected negative auto-regulation ([@B24]) or UVI-mediated miR125b regulation ([@B20]--[@B22]).

The relation between *VDR* methylation and functional variables (Table [4](#T4){ref-type="table"}) was best observed for VDR protein levels, with CpG sites across the enhancer (CGI 1066), promoter (CGI 1062), exon 3 (CGI 1061) and exon 9 (CGI 1060) showing power to discriminate individuals with above average VDR protein levels from those with below average levels. This supports, in part, the univariate correlation of regional methylation observed most commonly with VDR protein (Table [3](#T3){ref-type="table"}). The significant, large discriminatory power of CGI 1062 CpG 3 in the primary promoter of *VDR* to distinguish a 5.7-fold above average mean VDR protein level upon elicitation, may relate to the colocation of a binding site for the E2F transcription factor 7, a member of the V\$E2FF matrix family (Matrix Library 10.0, Genomatix 2016 ([@B35])), implicated in negative regulation of DNA binding and transcription ([@B45]). Comparing the V\$E2FF matrix to the sequence around CGI 1062 CpG 3, showed a matrix and core similarity of 1 and 0.875, respectively, with high conservation across the CpG 3 cytosine-guanine dinucleotide that forms part of the matrix core. Notably, a CpG-ruinous SNPs (C/G) in the second position of the dinucleotide, unique to Africans (5% "C," 1000 Genomes Browser), have been reported. The positive correlation between VDR protein level and methylation at CGI 1062 CpG 3 may support methylation-sensitive suppressor activity, alleviated by DNA methylation. The positive impact of CGI 1060 CpG 6 methylation, possible only when *Taq*I is "C," seen for VDR mRNA with supplementation or elicitation, support a TB case control finding from our laboratory showing concomitant decreased methylation of CGI 1060a associating with protection from TB ([@B34]) and correlating with increased VDR levels in the current study (Table [3](#T3){ref-type="table"}). The prominence of *Taq*I-based clustering across all variables and treatments, except for hCAP-18, further confirms the importance of this SNP, commonly found associated with diverse diseases and first reported to be associated with infectious disease by Bellamy et al. ([@B46]). Pam~3~CSK~4~ is a strong activator of NF-κB1 ([@B47]) and the negative impact of methylation at 1062 CpG 23 on hCAP-18 may relate to its location adjacent to an NF-κB1 and SP-1 binding site in the primary promoter of *VDR*.

Overall, it appears that individuals who respond with an above average level of VDR protein upon TLR2/1 elicitation display hypermethylation at CGI 1066 CpG 1 and 3, as well as at CGI 1062 CpG 3, while displaying hypomethylation at CGI 1061 CpG 9 and CGI 1060a CpG 1-4 (Figure [8](#F8){ref-type="fig"}). While the *VDR* SNP *Taq*I and 25(OH)D~3~ influenced the variation within the study population with elicitation, without 1,25(OH)~2~D~3~ supplementation, 25(OH)D~3~ status was no longer identified as a contributing factor upon 1,25(OH)~2~D~3~ supplementation. Moreover, the effect of several SNPs became apparent only in the presence 1,25(OH)~2~D~3~ supplementation. This suggests that 25(OH)D~3~ status may have a larger effect on TLR2/1, VDR-mediated signaling than these genetic variables.

![A schematic diagram summarizing factors influencing the signaling efficacy of the TLR2/1-VDR pathway in response to TLR2/1 elicitation. Pam~3~CSK~4~ (Pam~3~CysSerLys~4~), a synthetic tripalmitoylated lipopeptide, mimics the acylated amino terminus of bacterial lipoproteins and is recognized by TLR2, cooperating with TLR1 to induce signaling that activates the pro-inflammatory transcription factor NF-κB, inducing *CYP27B1* and *VDR*. Factors found to influence VDR expression are indicated in red. UVI correlated with 25(OH)D~3~, known to autoregulate *VDR*. Individuals who responded with an above average level of VDR protein upon TLR2/1 elicitation were hypermethylated at CGI 1066 (CpG 1 and 3) and CGI 1062 (CpG 3), while hypomethylated at CGI 1061 (CpG 9) and CGI 1060 (CpG 1--4). With *in vitro* 1,25(OH)~2~D~3~ supplementation CGI 1062 CpG 3 was slightly less discriminatory upon TLR2/1 elicitation, but remained a significant variable to discriminate above/below average VDR protein level. However, with supplementation the population clustered by race and all genetic variants indicated (*TLR1* SNP I602S, *TIRAP* SNP S180L, and *VDR* SNPs *Bsm*I, *Apa*I, and *Taq*I, see Table [4](#T4){ref-type="table"}), compared to clustering by vitamin D status and *Taq*I alone, without supplementation. Methylation at CpG 6 of CGI 1060 (dictated by *Taq*I, with which it overlaps) together with UVI and circulating 25(OH)D~3~, significantly discriminated a 1.2-1.5-fold change in VDR mRNA with supplement or elicitation. Abbreviations: *CAMP*, cathelicidin antimicrobial peptide; CGI, CpG island; CpG, cytosine-phosphate-guanine dinucleotide; CYP, cytochrome P-450 enzyme; *CYP24A1*, 25-hydroxyvitamin D~3~-24-hydroxylase; D~2~, ergocalciferol; D~3~, cholecalciferol; DBP, vitamin D binding protein; *GC*, group component or gene encoding DBP; hCAP-18, human cathelicidin antimicrobial peptide 18; LL-37, cathelicidin antimicrobial peptide fragment; 1,25(OH)~2~D~3~ 1,25-dihydroxycholecalciferol; 25(OH)D~3~, 25-hydroxycholecalciferol; NF-κB, nuclear factor kappa B; Pam~3~CSK~4~, synthetic tripalmitoylated lipohexapeptide, PTH parathyroid hormone; RXR retinoid X receptor; *TIRAP*, TIR, toll-interleukin 1 receptor domain-containing adaptor protein; TLR, toll-like receptor; UVB, ultraviolet B rays; UVI, ultraviolet index; *VDR*, vitamin D receptor gene; VDR, vitamin D receptor protein; VDRE, vitamin D receptor element.](fimmu-08-01048-g008){#F8}

Taken together, results presented here provide support for multifactorial regulation of VDR-mediated TLR2/1 signaling, involving interaction between environment, epigenetics, and genetics. UVI influences 25(OH)D~3~ status, which regulates VDR expression through *VDR* methylation, while enhancing the extent and rate of VDR transactivation of *CAMP* encoding the antimicrobial peptide hCAP-18. The complex interaction between these factors may shed further light on the disparity in infectious diseases across the globe.
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